Ustekinumab for Immune Checkpoint Inhibitor-related Diarrhea and Colitis
This study is looking into whether ustekinumab can help cancer patients who experience diarrhea and/or colitis (inflammation of the colon) as a side effect of immune checkpoint inhibitor (ICI) therapy. ICI therapy is a type of cancer treatment. We want to see if ustekinumab can reduce these symptoms and improve your quality of life. You might be able to join if you are 18 or older, are receiving ICI therapy, and have experienced at least moderate diarrhea and/or colitis related to your ICI treatment within 45 days of enrolling. The study will measure how safe ustekinumab is and how well it helps to control these side effects. The current status of this study is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 10 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
At a glance
Conditions
NCT06807593
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Texas M. D. Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Yinghong Wang, MD,PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse EventsThrough study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0